Yongjin Dapagliflozin 5mg (Dapagliflozin Monohydrate Mixture)
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Yongjin Pharmaceutical Co., Ltd.
MFDS item code 202005357 · Approved 2020.07.23
This product's status changed to Approval withdrawn on 2024.12.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps to effectively control blood sugar in patients with type 2 diabetes. It can be used alone or in combination with other medications alongside dietary and exercise therapy. It can be administered especially to patients who do not achieve adequate blood sugar control and have cardiovascular disease or risk factors. This medication may have a positive impact not only on blood sugar management but also on the reduction of the risk of cardiovascular events, so it should be used safely according to the patient's condition.
Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received antidiabetic drug therapy, the recommended initial dose of this medicine when administered in combination with metformin is 5mg once daily or 10mg once daily. This medicine may be taken orally once daily at any time of the day, with or without food. The tablet should be swallowed whole. Renal impairment Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate [estimated glomerular filtration rate (eGFR)] below 60 mL/min/1.73 m2. This medicine should be discontinued if the glomerular filtration rate remains below 45 mL/min/1.73 m2. No dose adjustment is necessary in patients with mild renal impairment. Hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) In general, dose adjustment based on age is not recommended. Renal function and the risk of volume depletion should be considered. As treatment experience in patients over 75 years of age is limited, initiation of treatment with this medicine is not recommended.
This medication should not be used in certain patients. It should not be administered to patients who are allergic to the main component or additives of this medication, patients with type 1 diabetes, patients with diabetic ketoacidosis, and patients with genetic lactose intolerance issues. Additionally, it should not be used in patients with severely impaired kidney function, end-stage kidney disease, or those undergoing dialysis. Patients with kidney function problems or suspected acute kidney injury should use this medication with caution. Especially patients with reduced blood volume, chronic kidney failure, heart failure, or those taking diuretics or specific antihypertensive medications are at higher risk of acute kidney injury and should have their condition checked carefully before administration. If fluid loss occurs, drug administration should be temporarily suspended and kidney function should be closely monitored. In patients with severe symptoms of heart failure, the use of this medication is not recommended, and caution is required for patients allergic to the colorants included in the medication. Using this medication may result in hypoglycemia, decreased fluid volume, infections (particularly genital and urinary tract infections), abnormal kidney function, changes in specific hormone levels in the blood, etc. Hypoglycemia is especially more likely to occur when taken together with insulin or sulfonylureas, so caution should be exercised. Pregnant or breastfeeding women should not use this medication, and the safety for children has not been established. This medication should be used with caution in patients at risk of dehydration or hypotension, as serious metabolic disturbances such as ketoacidosis may occur, and immediate consultation with medical personnel is necessary if symptoms arise. This medication may interact with other drugs, so especially when taken with diuretics, insulin, or insulin secretagogues, the doctor's instructions should be closely followed. In case of overdose, appropriate treatment is required based on symptoms, and while this medication has minimal effects on driving or machine operation capabilities, caution is needed due to the risk of hypoglycemia. This medication may be restricted or not recommended for specific patient groups such as children, pregnant women, and patients with severely impaired kidney or liver function, so medical consultation is required.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture; therefore, it should be stored in a sealed container. Storage temperature should be suitable at room temperature between 1 to 30 degrees Celsius, avoiding very hot or cold places.
Yellow, biconvex, round film-coated tablet
28 tablets/box [(7 tablets/PTP x 4)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Yongjin Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.